Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD

Sponsor
Assiut University
Study ID
NCT06820567
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chronic Kidney Diseases
  • Diabetes Type 2

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin (DAPA) — DRUG
    patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients
  • Placebo — DRUG
    type 2 diabetic patients with chronic kidney diseases will recive placebo for 24 weeks

Study Details

the effect of Dapagliflozin on erythropoiesis, iron metabolism and inflammatory markers in CKD with Type 2 DM-Compare between effect of placebo and dapagliflozin on erythropoiesis, iron metabolism and inflammation markers in CKD with Type 2 DM.

Key Dates

Start date
Mar 1, 2025
Status verified
Feb 2025
Primary completion
Mar 1, 2026
Completion
May 1, 2027

Study Design

Enrollment
210 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A
    type 2 diabetic patients with chronic kidney diseases will recive dapagliflozin
  • Placebo Comparator: Group B
    type 2 diabetic patients with chronic kidney diseases will recive placebo

Primary Outcome Measure

GFR in CKD patients [ Time Frame: 6 months ]

Central Contacts

Related coverage on Hipa.ai

Related Studies